Evidence map›Paper›PMID 38501158›Full record

ReviewJournal of medical radiation sciences2024

Proton beam therapy for clival chordoma: Optimising rare cancer treatments in Australia.

Ashwathy Mathew, Peter Gorayski, Nicholas Candy, Frank Saran, Hien Le

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of medical radiation sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ashwathy MathewDepartment of Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0003-4781-5461
Peter GorayskiDepartment of Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0001-7340-0978
Nicholas CandyDepartment of Surgery, The University of Adelaide, Adelaide, South Australia, Australia.
Frank SaranDepartment of Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.
Hien LeDepartment of Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.
Royal Adelaide Hospital · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the anticipated launch of the Australian Bragg Centre for Proton Therapy and Research (ABCPTR) in Adelaide, Australia, proton therapy will become a significant addition to existing cancer treatment options for Australians. The anticipated benefits will be particularly evident in rare cancers such as clival chordomas, a challenging tumour entity due to the anatomical relationship with critical structures, and proven radio-resistance to conventional radiation therapy. The article synthesises key findings from major studies and evaluates the current evidence supporting various management strategies for clival chordomas. It also considers the influence of institutional volume and multidisciplinary team management on patient outcomes and outlines how high-quality care can be effectively delivered within the Australian healthcare system, emphasising the potential impact of proton therapy on the treatment paradigm of clival chordomas in Australia.

Indexed as

ChordomaHead and Neck NeoplasmsProton TherapySkull Base NeoplasmsAustraliaHumanscancerChordomaproton therapyradiation therapyrare cancerssarcoma

Identifiers

PMID38501158
PMCPMC11011593
OpenAlexW4392963340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.